Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.

Inclusion Criteria: 1. Patients indicated for gastroscopy examination; 2. Subjects fully understand the content, process, and possible adverse reactions of the trial and voluntary participation with signed informed consent; 3. Able to complete the research according to the requirements of the experimental plan; 4. Subjects (including their spouses) voluntarily have no pregnancy plans and use contraception during the study and within 3 months after the last administration of the study drug; 5. Aged 18-75 years (inclusive), male or female; Exclusion Criteria: 1. Known allergy to chymotrypsin; Known to be allergic to preparation or anesthesia medication before gastroscopy examination; 2. Patients plan to undergo gastroscopic treatment, such as endoscopic titanium clip for hemostasis, esophagogastric fundal variceal ligation, endoscopic mucosal stripping, etc; 3. Subjects accessed not to stand sedation anesthesia or gastroscopy examination; 4. Severe cardiovascular, pulmonary, or cerebral diseases, such as angina, heart failure, and new-onset stroke; or severe liver disease, cirrhosis, or esophagogastric fundus varices; 5. Suspected or known esophageal fistula, tracheal fistula, intestinal obstruction, active gastrointestinal bleeding, gastric perforation, history of anatomically altered upper GI surgery; 6. Abnormal laboratory values:: alanine aminotransferase (ALT)\>2 × ULN, aspartate aminotransferase (AST)\>2 × ULN, serum creatinine\>1.5 × ULN; 7. Female subjects who had unprotected sex within 14 days prior to screening; 8. Pregnant or breastfeeding women; 9. Subjects who have participated in any drug clinical trial and received treatment within the last 3 months; 10. Any other conditions deemed unsuitable for the study by the investigator.